January 22, 2019
Weil was recently profiled by Law360 as a 2018 nationwide Life Sciences “Practice Group of the Year” for amassing numerous wins in federal court in the past year.
The profile highlighted the Firm’s representation of Illumina in securing a $26.7 million jury verdict in a high-profile patent infringement dispute against Ariosa Diagnostics. The verdict marks the culmination of six years of litigation involving the invention of a revolutionary Down syndrome blood test that is replacing the invasive and risky traditional amniocentesis test. Edward Reines noted the test as a huge step forward for medical health worldwide. “We vindicated the approach of our clients to inventing and disseminating a blood test for Down syndrome that is in the process of replacing amniocentesis,” a process that is not only expensive, but can be painful and can lead to termination of pregnancy.
The Firm was also highlighted for its win before the U.S. Court of Appeals for the Federal Circuit on behalf of client Life Technologies Corp., a genetic testing company, in its patent dispute with Promega Corp. over gene testing technology. A federal judge granted Life Technologies’ post-trial motion for judgment as a matter of law, vacating a $52 million verdict awarded to Promega. "Weil is in the business of helping clients problem-solve, and solving the problem of a $52 million verdict by helping to zero it out is obviously the kind of result we like to provide to our clients," Mr. Reines said of the successful verdict.
The article noted the development of the Firm’s formal establishment of the Life Sciences practice in 2018, led by Mr. Reines and Elizabeth Weiswasser serving as Co-Heads of the practice, in addition to serving as Co-Heads of the Firm’s Patent Litigation practice. The Firm’s flourishing practice is comprised of Weil attorneys with experience across various disciplines, including pharmaceutical litigation, biotechnology and product liability.
When discussing the newly formed Life Sciences practice, Ms. Weiswasser emphasized Weil has a “long-standing and deep dedication to working with clients in the pharmaceutical, biotech and medical device industries, and has developed a strong and deep bench of attorneys who have unique expertise in the technologies and specific issues that clients in that overall industry face."
On the future of the practice, Ms. Weiswasser commented, “We're looking forward to continuing and expanding our partnership with life science companies to promote innovation in the overall area of human health, and continuing our commitment to excellence in developing teams of attorneys that are uniquely positioned to help our clients address their legal needs in this space."